Pulmonary drug delivery is expanding beyond traditional indications such as asthma and chronic obstructive pulmonary disease (COPD), with the inhalable drugs sector projected to grow from approximately $36 billion in 2023 to nearly $60 billion by 2030. This growth is driven by innovative therapies and delivery methods, particularly in dry powder systems and other inhaled dosage forms. As developers explore inhalation for diverse therapeutic categories, including oncology and neuropsychiatric treatments, the complexity of inhalation drug development becomes evident.
Inhalation products must be designed as integrated systems, where formulation, particle engineering, device architecture, and manufacturing processes evolve in tandem. A common misconception is that formulation can be optimized independently of the delivery device. However, the device plays a crucial role in determining aerosol performance and drug deposition in the respiratory tract. Early evaluation of device performance under realistic conditions is essential to avoid costly redesigns and operational bottlenecks later in development.
As inhalation technologies extend into new therapeutic areas, the demands on particle engineering and device design will increase. Successful inhalation programs will require a coordinated approach that integrates formulation, device development, and clinical supply strategies from the outset, ensuring that inhalation is treated as a complex system rather than a series of isolated challenges.
Open the full market picture for your next decision →
